Avocet Bio exemplifies how the next wave of breakthrough innovation can emerge from versatile RNA-targeting platform technologies that integrate molecular biology with data-driven refinement. Our approach combines CRISPR-Cas13 modalities with bioinformatics and AI-guided target selection to accelerate the path from discovery to effective RNA-based medicines.
We are currently seeking investment from private investors, venture capital firms, and other entities to further support and expand our research and development efforts.
We are open to seed rounds to propel our program into first-in-human clinical trials.
